Larimar Therapeutics, Inc.
LRMR
$3.44
-$0.06-1.71%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.13% | -116.83% | -207.84% | -21.06% | -99.82% |
| Total Depreciation and Amortization | -27.27% | 12.99% | 18.92% | 0.00% | 10.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 78.02% | 12.81% | 602.53% | 169.58% | -32.16% |
| Change in Net Operating Assets | -1,132.99% | 291.65% | 287.57% | -23.36% | -38.59% |
| Cash from Operations | -68.10% | -76.61% | -17.14% | -38.55% | -154.92% |
| Capital Expenditure | -- | 100.00% | 62.90% | 93.07% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.04% | 75.47% | 20.88% | 129.83% | 121.21% |
| Cash from Investing | 100.72% | 77.11% | 21.07% | 129.68% | 121.13% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 217,523.33% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -658.33% | 217,523.33% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 864.98% | -83.11% | 2,423.69% | 99.31% | -114.50% |